<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39350170</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1297-9716</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Veterinary research</Title><ISOAbbreviation>Vet Res</ISOAbbreviation></Journal><ArticleTitle>Use of virus-like particles and nanoparticle-based vaccines for combating picornavirus infections.</ArticleTitle><Pagination><StartPage>128</StartPage><MedlinePgn>128</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">128</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13567-024-01383-x</ELocationID><Abstract><AbstractText>Picornaviridae are non-enveloped ssRNA viruses that cause diseases such as poliomyelitis, hand-foot-and-mouth disease (HFMD), hepatitis A, encephalitis, myocarditis, and foot-and-mouth disease (FMD). Virus-like particles (VLPs) vaccines mainly comprise particles formed through the self-assembly of viral capsid proteins (for enveloped viruses, envelope proteins are also an option). They do not contain the viral genome. On the other hand, the nanoparticles vaccine (NPs) is mainly composed of self-assembling biological proteins or nanomaterials, with viral antigens displayed on the surface. The presentation of viral antigens on these particles in a repetitive array can elicit a strong immune response in animals. VLPs and NPs can be powerful platforms for multivalent antigen presentation. This review summarises the development of virus-like particle vaccines (VLPs) and nanoparticle vaccines (NPs) against picornaviruses. By detailing the progress made in the fight against various picornaviruses such as poliovirus (PV), foot-and-mouth disease virus (FMDV), enterovirus (EV), Senecavirus A (SVA), and encephalomyocarditis virus (EMCV), we in turn highlight the significant strides made in vaccine technology. These advancements include diverse construction methods, expression systems, elicited immune responses, and the use of various adjuvants. We see promising prospects for the continued development and optimisation of VLPs and NPs vaccines. Future research should focus on enhancing these vaccines' immunogenicity, stability, and delivery methods. Moreover, expanding our understanding of the interplay between these vaccines and the immune system will be crucial. We hope these insights will inspire and guide fellow researchers in the ongoing quest to combat picornavirus infections more effectively.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, CollegeofVeterinaryMedicine, Lanzhou UniversityLanzhou Veterinary Research InstituteChinese Academy of Agricultural Sciences, Lanzhou, 730000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gembloux Agro-Biotech, University of Liege, Gembloux, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdullah</LastName><ForeName>Sahibzada Waheed</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Livestock and dairy development department peshawar, Government of Khyber Pakhtunkhwa, Peshawar, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pei</LastName><ForeName>Chenchen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, CollegeofVeterinaryMedicine, Lanzhou UniversityLanzhou Veterinary Research InstituteChinese Academy of Agricultural Sciences, Lanzhou, 730000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Huichen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, CollegeofVeterinaryMedicine, Lanzhou UniversityLanzhou Veterinary Research InstituteChinese Academy of Agricultural Sciences, Lanzhou, 730000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Shiqi</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4975-739X</Identifier><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, CollegeofVeterinaryMedicine, Lanzhou UniversityLanzhou Veterinary Research InstituteChinese Academy of Agricultural Sciences, Lanzhou, 730000, China. sunshiqi@caas.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NASC2024KR06</GrantID><Agency>Local Financial Funds of National Agricultural Science and Technology Center, Chengdu</Agency><Country /></Grant><Grant><GrantID>2023-RC-3</GrantID><Agency>Lanzhou Talent Innovation and Entrepreneurship Project</Agency><Country /></Grant><Grant><GrantID>23ZDNA007</GrantID><Agency>the Science and Technology Major Project of Gansu Provine</Agency><Country /></Grant><Grant><GrantID>22JR5RA032</GrantID><Agency>Natural Science Foundation of Gansu Province</Agency><Country /></Grant><Grant><GrantID>23JRRA551</GrantID><Agency>Natural Science Foundation of Gansu Province</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Vet Res</MedlineTA><NlmUniqueID>9309551</NlmUniqueID><ISSNLinking>0928-4249</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010850" MajorTopicYN="Y">Picornaviridae Infections</DescriptorName><QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="Y">Vaccines, Virus-Like Particle</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010849" MajorTopicYN="Y">Picornaviridae</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Virus-like particles</Keyword><Keyword MajorTopicYN="N">adjuvant</Keyword><Keyword MajorTopicYN="N">nanoparticles</Keyword><Keyword MajorTopicYN="N">picornavirus</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>7</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>7</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39350170</ArticleId><ArticleId IdType="pmc">PMC11443892</ArticleId><ArticleId IdType="doi">10.1186/s13567-024-01383-x</ArticleId><ArticleId IdType="pii">10.1186/s13567-024-01383-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bolanos-Martinez OC, Rosales-Mendoza S (2020) The potential of plant-made vaccines to fight picornavirus. Expert Rev Vaccines 19:599–610</Citation><ArticleIdList><ArticleId IdType="pubmed">32609047</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YY, Chen Y, Wei X, Cui J (2022) Viromes in marine ecosystems reveal remarkable invertebrate RNA virus diversity. Sci China Life Sci 65:426–437</Citation><ArticleIdList><ArticleId IdType="pubmed">34156600</ArticleId></ArticleIdList></Reference><Reference><Citation>Picornavirus home. https://picornaviridae.com.</Citation></Reference><Reference><Citation>Uwishema O, Elebesunu EE, Bouaddi O, Kapoor A, Akhtar S, Effiong FB, Chaudhary A, Onyeaka H (2022) Poliomyelitis amidst the covid-19 pandemic in Africa: efforts, challenges and recommendations. Clin Epidemiol Glob Health 16:101073</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9148425</ArticleId><ArticleId IdType="pubmed">35664665</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinobe R, Wiyatno A, Artika IM, Safari D (2022) Insight into the enterovirus a71: a review. Rev Med Virol 32:e2361</Citation><ArticleIdList><ArticleId IdType="pubmed">35510476</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang YJ, Shi C, Zhou J, Qian J, Qiu Y, Ge G (2022) Multiple molecular characteristics of circulating enterovirus types among pediatric hand, foot and mouth disease patients after ev71 vaccination campaign in Wuxi, China. Epidemiol Infect 150:1–19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9128351</ArticleId><ArticleId IdType="pubmed">35473720</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobotka LA, Mumtaz K, Hinton A, Porter K, Conteh LF (2022) National report on healthcare utilization and mortality in patients with hepatitis a infection in the United States. Public Health 207:113–118</Citation><ArticleIdList><ArticleId IdType="pubmed">35636263</ArticleId></ArticleIdList></Reference><Reference><Citation>Han R, Liang L, Qin T, Xiao S, Liang R (2022) Encephalomyocarditis virus 2A protein inhibited apoptosis by interaction with annexin A2 through JNK/c-jun pathway. Viruses 14:359</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8880565</ArticleId><ArticleId IdType="pubmed">35215950</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Wang R, Bai M, Wang X, Dong H, Li J, Mu S, Miao H, Song J, Sun S, Guo H (2022) Development of a competitive ELISA method based on VLPS detecting the antibodies of serotype A FMDV. J Virol Methods 300:114406</Citation><ArticleIdList><ArticleId IdType="pubmed">34915087</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JY, Chen TC, Weng KF, Chang SC, Chen LL, Shih SR (2009) Viral and host proteins involved in picornavirus life cycle. J Biomed Sci 16:103</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785775</ArticleId><ArticleId IdType="pubmed">19925687</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A, Garlanda C (2023) Humoral innate immunity and acute-phase proteins. N Engl J Med 388:439–452</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9912245</ArticleId><ArticleId IdType="pubmed">36724330</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla FA, Oettgen HC (2010) Adaptive immunity. J Allergy Clin Immunol 125:S33-40</Citation><ArticleIdList><ArticleId IdType="pubmed">20061006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutmoller P, Casas OR (2002) Unapparent foot and mouth disease infection (sub-clinical infections and carriers): implications for control. Rev Sci Tech 21:519–529</Citation><ArticleIdList><ArticleId IdType="pubmed">12523693</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu JJ, Stenfeldt C, Bishop EA, Canter JA, Eschbaumer M, Rodriguez LL, Arzt J (2020) Mechanisms of maintenance of foot-and-mouth disease virus persistence inferred from genes differentially expressed in nasopharyngeal epithelia of virus carriers and non-carriers. Front Vet Sci 7:340</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7318773</ArticleId><ArticleId IdType="pubmed">32637426</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexandersen S, Zhang Z, Donaldson AI (2002) Aspects of the persistence of foot-and-mouth disease virus in animals–the carrier problem. Microbes Infect 4:1099–1110</Citation><ArticleIdList><ArticleId IdType="pubmed">12191660</ArticleId></ArticleIdList></Reference><Reference><Citation>Doel TR, Williams L, Barnett PV (1994) Emergency vaccination against foot-and-mouth disease: rate of development of immunity and its implications for the carrier state. Vaccine 12:592–600</Citation><ArticleIdList><ArticleId IdType="pubmed">8085375</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis MJ (2018) Recent advances in vaccine technologies. Vet Clin North Am Small Anim Pract 48:231–241</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132473</ArticleId><ArticleId IdType="pubmed">29217317</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahrokhian SH, Tostanoski LH, Vidal SJ, Barouch DH (2024) Covid-19 vaccines: immune correlates and clinical outcomes. Hum Vaccin Immunother 20:2324549</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10962618</ArticleId><ArticleId IdType="pubmed">38517241</ArticleId></ArticleIdList></Reference><Reference><Citation>Ming LC, Hussain Z, Yeoh SF, Koh D, Lee KS (2020) Circulating vaccine-derived poliovirus: a menace to the end game of polio eradication. Global Health 16:63</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7364572</ArticleId><ArticleId IdType="pubmed">32677974</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, Middelberg AP (2014) Nanoparticle vaccines. Vaccine 32:327–337</Citation><ArticleIdList><ArticleId IdType="pubmed">24295808</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeltins A (2013) Construction and characterization of virus-like particles: a review. Mol Biotechnol 53:92–107</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7090963</ArticleId><ArticleId IdType="pubmed">23001867</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhakal S, Renukaradhya GJ (2019) Nanoparticle-based vaccine development and evaluation against viral infections in pigs. Vet Res 50:90</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6833244</ArticleId><ArticleId IdType="pubmed">31694705</ArticleId></ArticleIdList></Reference><Reference><Citation>Demento SL, Cui W, Criscione JM, Stern E, Tulipan J, Kaech SM, Fahmy TM (2012) Role of sustained antigen release from nanoparticle vaccines in shaping the T-cell memory phenotype. Biomaterials 33(19):4957–4964</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5724530</ArticleId><ArticleId IdType="pubmed">22484047</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen ZS, Xu YL, Zou XT, Xu ZR (2011) Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Mar Drugs 9:1038–1055</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3131560</ArticleId><ArticleId IdType="pubmed">21747747</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamayo I, Irache JM, Mansilla C, Ochoa-Repáraz J, Lasarte JJ, Gamazo C (2010) Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation. Clin Vaccine Immunol 17:1356–1362</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944445</ArticleId><ArticleId IdType="pubmed">20631332</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandrup Schmidt S, Foged C, Korsholm KS, Rades T, Christensen D (2016) Liposome-based adjuvants for subunit vaccines: formulation strategies for subunit antigens and immunostimulators. Pharmaceutics 8:7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4810083</ArticleId><ArticleId IdType="pubmed">26978390</ArticleId></ArticleIdList></Reference><Reference><Citation>Perotti M, Perez L (2019) Virus-like particles and nanoparticles for vaccine development against HCMV. Viruses 12:35</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7019358</ArticleId><ArticleId IdType="pubmed">31905677</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalaj-Hedayati A, Chua CLL, Smooker P, Lee KW (2020) Nanoparticles in influenza subunit vaccine development: immunogenicity enhancement. Influenza Other Respir Viruses 14:92–101</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6928032</ArticleId><ArticleId IdType="pubmed">31774251</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo HC, Sun SQ, Jin Y, Yang SL, Wei YQ, Sun DH, Yin SH, Ma JW, Liu ZX, Guo JH, Luo JX, Yin H, Liu XT, Liu DX (2013) Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in Escherichia coli induce potent protective immune responses in guinea pigs, swine and cattle. Vet Res 44:48</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3720265</ArticleId><ArticleId IdType="pubmed">23826638</ArticleId></ArticleIdList></Reference><Reference><Citation>Rani D, Nayak B, Srivastava S (2021) Immunogenicity of gold nanoparticle-based truncated ORF2 vaccine in mice against hepatitis E virus. 3 Biotech 11:49</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799426</ArticleId><ArticleId IdType="pubmed">33457173</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Lysebetten D, Malfanti A, Deswarte K, Koynov K, Golba B, Ye T, Zhong Z, Kasmi S, Lamoot A, Chen Y, Van Herck S, Lambrecht BN, Sanders NN, Lienenklaus S, David SA, Vicent MJ, De Koker S, De Geest BG (2021) Lipid-polyglutamate nanoparticle vaccine platform. ACS Appl Mater Interfaces 13:6011–6022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116839</ArticleId><ArticleId IdType="pubmed">33507728</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Farooq MA, Li T, Geng T, Kutoka PT, Wang B (2021) Cationic chitosan-modified silica nanoparticles for oral delivery of protein vaccine. J Biomed Mater Res A 109:2111–2119</Citation><ArticleIdList><ArticleId IdType="pubmed">33871158</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Deen FN, Selomulya C, Ma C, Coppel RL (2014) Superparamagnetic nanoparticle delivery of DNA vaccine. Methods Mol Biol 1143:181–194</Citation><ArticleIdList><ArticleId IdType="pubmed">24715289</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Hu Y, Chen H, Li X, Qian P (2020) A ferritin nanoparticle vaccine for foot-and-mouth disease virus elicited partial protection in mice. Vaccine 38:5647–5652</Citation><ArticleIdList><ArticleId IdType="pubmed">32624251</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell RA, Diamond MS, Colonna M (2006) Essential role of mda-5 in type i ifn responses to polyriboinosinic: polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci USA 103:8459–8464</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1464000</ArticleId><ArticleId IdType="pubmed">16714379</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberger J, Skern T (2014) The leader proteinase of foot-and-mouth disease virus: structure-function relationships in a proteolytic virulence factor. Biol Chem 395:1179–1185</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4931897</ArticleId><ArticleId IdType="pubmed">24670358</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Weiss M, Grubman MJ, de los Santos T (2010) Differential gene expression in bovine cells infected with wild type and leaderless foot-and-mouth disease virus. Virology 404:32–40</Citation><ArticleIdList><ArticleId IdType="pubmed">20494391</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamal SM, Belsham GJ (2013) Foot-and-mouth disease: past, present and future. Vet Res 44:116</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4028749</ArticleId><ArticleId IdType="pubmed">24308718</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchweger R, Ziegler E, Lamphear BJ, Waters D, Liebig HD, Sommergruber W, Sobrino F, Hohenadl C, Blaas D, Rhoads RE (1994) Foot-and-mouth disease virus leader proteinase: purification of the lb form and determination of its cleavage site on eIF-4 gamma. J Virol 68:5677–5684</Citation><ArticleIdList><ArticleId IdType="pmc">PMC236969</ArticleId><ArticleId IdType="pubmed">8057448</ArticleId></ArticleIdList></Reference><Reference><Citation>Weerawardhana A, Uddin MB, Choi JH, Pathinayake P, Shin SH, Chathuranga K, Park JH, Lee JS (2022) Foot-and-mouth disease virus non-structural protein 2B downregulates the RLR signaling pathway via degradation of RIG-I and MDA5. Front Immunol 13:1020262</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556895</ArticleId><ArticleId IdType="pubmed">36248821</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, Li C, Du X, Wang G, Cao W, Yang F, Feng H, Zhang X, Shi Z, Liu H, Tian H, Li D, Zhang K, Liu X, Zheng H (2017) Foot-and-mouth disease virus infection inhibits LGP2 protein expression to exaggerate inflammatory response and promote viral replication. Cell Death Dis 8:e2747</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5477588</ArticleId><ArticleId IdType="pubmed">28406479</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Xue Q, Zhu Z, Yang F, Cao W, Liu X, Zheng H (2021) Foot-and-mouth disease virus inhibits rip2 protein expression to promote viral replication. Virol Sin 36:608–622</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8379319</ArticleId><ArticleId IdType="pubmed">33400090</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekanayaka P, Lee SY, Herath TUB, Kim JH, Kim TH, Lee H, Chathuranga K, Chathuranga WAG, Park JH, Lee JS (2020) Foot-and-mouth disease virus VP1 target the MAVS to inhibit type-I interferon signaling and VP1 E83K mutation results in virus attenuation. PLoS Pathog 16:e1009057</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723281</ArticleId><ArticleId IdType="pubmed">33232374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekanayaka P, Lee BH, Weerawardhana A, Chathuranga K, Park JH, Lee JS (2021) Inhibition of mavs aggregation-mediated type-I interferon signaling by foot-and-mouth disease virus VP3. Viruses 13:1773</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8473216</ArticleId><ArticleId IdType="pubmed">34578357</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Liang Y, Qu L, Chen Z, Yi M, Li K, Lemon SM (2007) Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proc Natl Acad Sci USA 104:7253–7258</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1855380</ArticleId><ArticleId IdType="pubmed">17438296</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu L, Feng Z, Yamane D, Liang Y, Lanford RE, Li K, Lemon SM (2011) Disruption of TLR3 signaling due to cleavage of TRIF by the hepatitis A virus protease-polymerase processing intermediate, 3CD. PLoS Pathog 7:e1002169</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169542</ArticleId><ArticleId IdType="pubmed">21931545</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabir A, Ullah K, Ali Kamboh A, Abubakar M, Shafiq M, Wang L (2024) The pathogenesis of foot-and-mouth disease virus infection: how the virus escapes from immune recognition and elimination. Arch Immunol Ther Exp 72:13</Citation><ArticleIdList><ArticleId IdType="pubmed">38910298</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina GN, Segundo FD, Stenfeldt C, Arzt J, de Los ST (2018) The different tactics of foot-and-mouth disease virus to evade innate immunity. Front Microbiol 9:2644</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6241212</ArticleId><ArticleId IdType="pubmed">30483224</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Q, Ren S, Dou Y, Tadele BA, Hu T, Zhou L, Wang T, Yao K, Xu J, Yin X, Sun Y (2024) Foot-and-mouth disease virus capsid protein VP1 antagonizes type I interferon signaling via degradation of histone deacetylase 5. Cells 13:539</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10969541</ArticleId><ArticleId IdType="pubmed">38534383</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao K, Zhang S, Liu X, Guo X, Guo Z, Zhang X, Yuan W (2022) The game between host antiviral innate immunity and immune evasion strategies of senecavirus A—a cell biological perspective. Front Immunol 13:1107173</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9813683</ArticleId><ArticleId IdType="pubmed">36618383</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Zhu Z, Xue Q, Yang F, Li Z, Xue Z, Cao W, He J, Guo J, Liu X, Shaw AE, King DP, Zheng H (2023) Innate sensing of picornavirus infection involves cGAS-STING-mediated antiviral responses triggered by mitochondrial DNA release. PLoS Pathog 19:e1011132</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9934381</ArticleId><ArticleId IdType="pubmed">36745686</ArticleId></ArticleIdList></Reference><Reference><Citation>Yatim KM, Lakkis FG (2015) A brief journey through the immune system. Clin J Am Soc Nephrol 10:1274–1281</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4491295</ArticleId><ArticleId IdType="pubmed">25845377</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, Wang X, Li S, Saif Ur Rahman M, Xu S, Liu Y (2023) Nanovaccines for advancing long-lasting immunity against infectious diseases. ACS Nano 17:24514–24538</Citation><ArticleIdList><ArticleId IdType="pubmed">38055649</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen B, Tolia NH (2021) Protein-based antigen presentation platforms for nanoparticle vaccines. NPJ Vaccines 6:70</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8119681</ArticleId><ArticleId IdType="pubmed">33986287</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls AC, Fiala B, Schäfer A, Wrenn S, Pham MN, Murphy M, Tse LV, Shehata L, O’Connor MA, Chen C, Navarro MJ, Miranda MC, Pettie D, Ravichandran R, Kraft JC, Ogohara C, Palser A, Chalk S, Lee EC, Guerriero K, Kepl E, Chow CM, Sydeman C, Hodge EA, Brown B, Fuller JT, Dinnon KH 3rd, Gralinski LE, Leist SR, Gully KL, Lewis TB, Guttman M, Chu HY, Lee KK, Fuller DH, Baric RS, Kellam P, Carter L, Pepper M, Sheahan TP, Veesler D, King NP (2020) Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183:1367–1382.e17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7604136</ArticleId><ArticleId IdType="pubmed">33160446</ArticleId></ArticleIdList></Reference><Reference><Citation>Touabi L, Aflatouni F, McLean GR (2021) Mechanisms of rhinovirus neutralisation by antibodies. Viruses 13:360</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7996599</ArticleId><ArticleId IdType="pubmed">33668934</ArticleId></ArticleIdList></Reference><Reference><Citation>Cifuente JO, Moratorio G (2019) Evolutionary and structural overview of human picornavirus capsid antibody evasion. Front Cell Infect Microbiol 9:283</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6710328</ArticleId><ArticleId IdType="pubmed">31482072</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhyaya S, Ayelet G, Paul G, King DP, Paton DJ, Mahapatra M (2014) Genetic basis of antigenic variation in foot-and-mouth disease serotype A viruses from the middle east. Vaccine 32:631–638</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898079</ArticleId><ArticleId IdType="pubmed">24035435</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Zheng B, Zhang L, Cui L, Su X, Zhang Q, Guo Z, Guo Y, Zhang W, Zhu L, Zhu F, Rao Z, Wang X (2020) Serotype specific epitopes identified by neutralizing antibodies underpin immunogenic differences in enterovirus B. Nat Commun 11:4419</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7474084</ArticleId><ArticleId IdType="pubmed">32887892</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SY, Lee YJ, Kim RH, Park JN, Park ME, Ko MK, Choi JH, Chu JQ, Lee KN, Kim SM, Tark D, Lee HS, Ko YJ, Seo MG, Park JW, Kim B, Lee MH, Lee JS, Park JH (2017) Rapid engineering of foot-and-mouth disease vaccine and challenge viruses. J Virol 91:e00155-17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5533925</ArticleId><ArticleId IdType="pubmed">28566375</ArticleId></ArticleIdList></Reference><Reference><Citation>Belsham GJ (2020) Towards improvements in foot-and-mouth disease vaccine performance. Acta Vet Scand 62:20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7240906</ArticleId><ArticleId IdType="pubmed">32434544</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JY, Kung YA, Shih SR (2019) Antivirals and vaccines for enterovirus A71. J Biomed Sci 26:65</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6720414</ArticleId><ArticleId IdType="pubmed">31481071</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay AS, Lopez Cavestany R, Blake IM, Macklin G, Cooper L, Grassly N, Nery A, Mach O (2024) Use of inactivated poliovirus vaccine for poliovirus outbreak response. Lancet Infect Dis 24:e328–e342</Citation><ArticleIdList><ArticleId IdType="pubmed">38012892</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh MT, Bujaki E, Dolan PT, Smith M, Wahid R, Konz J, Weiner AJ, Bandyopadhyay AS, Van Damme P, De Coster I, Revets H, Macadam A, Andino R (2020) Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe 27:736–751.e8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Lu Z, Liu Z (2016) Foot-and-mouth disease vaccines: progress and problems. Expert Rev Vaccines 15:783–789</Citation><ArticleIdList><ArticleId IdType="pubmed">26760264</ArticleId></ArticleIdList></Reference><Reference><Citation>Andino R, Domingo E (2015) Viral quasispecies. Virology 479–480:46–51</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826558</ArticleId><ArticleId IdType="pubmed">25824477</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer JK, Kirkegaard K (2003) A single mutation in poliovirus rna-dependent rna polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci USA 100:7289–7294</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165868</ArticleId><ArticleId IdType="pubmed">12754380</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H, Guo HC, Sun SQ (2014) Virus-like particles in picornavirus vaccine development. Appl Microbiol Biotechnol 98:4321–4329</Citation><ArticleIdList><ArticleId IdType="pubmed">24647496</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohsen MO, Bachmann MF (2022) Virus-like particle vaccinology, from bench to bedside. Cell Mol Immunol 19:993–1011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9371956</ArticleId><ArticleId IdType="pubmed">35962190</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll EC, Jin L, Mori A, Muñoz-Wolf N, Oleszycka E, Moran HBT, Mansouri S, McEntee CP, Lambe E, Agger EM, Andersen P, Cunningham C, Hertzog P, Fitzgerald KA, Bowie AG, Lavelle EC (2016) The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons. Immunity 44:597–608</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4852885</ArticleId><ArticleId IdType="pubmed">26944200</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Min M, Du N, Gu Y, Hode T, Naylor M, Chen D, Nordquist RE, Chen WR (2013) Chitin, chitosan, and glycated chitosan regulate immune responses: the novel adjuvants for cancer vaccine. Clin Dev Immunol 2013:387023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3603646</ArticleId><ArticleId IdType="pubmed">23533454</ArticleId></ArticleIdList></Reference><Reference><Citation>Nooraei S, Bahrulolum H, Hoseini ZS, Katalani C, Hajizade A, Easton AJ, Ahmadian G (2021) Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnol 19:59</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7905985</ArticleId><ArticleId IdType="pubmed">33632278</ArticleId></ArticleIdList></Reference><Reference><Citation>Montross L, Watkins S, Moreland RB, Mamon H, Caspar DL, Garcea RL (1991) Nuclear assembly of polyomavirus capsids in insect cells expressing the major capsid protein VP1. J Virol 65:4991–4998</Citation><ArticleIdList><ArticleId IdType="pmc">PMC248962</ArticleId><ArticleId IdType="pubmed">1651418</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineo CB, Hitzeroth II, Rybicki EP (2013) Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras. Plant Biotechnol J 11:964–975</Citation><ArticleIdList><ArticleId IdType="pubmed">23924054</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HZ, Gang HY, Sun QM, Liu X, Ma YB, Sun MS, Dai CB (2004) Production in Pichia pastoris and characterization of genetic engineered chimeric HBV/HEV virus-like particles. Chin Med Sci J 19:78–83</Citation><ArticleIdList><ArticleId IdType="pubmed">15250239</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF 3rd, Glenn GM (2013) Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine 31:4305–4313</Citation><ArticleIdList><ArticleId IdType="pubmed">23891795</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Liang M, Gu W, Li C, Miao F, Wang X, Jin C, Zhang L, Zhang F, Zhang Q, Jiang L, Li M, Li D (2011) Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice. Virol J 8:333</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144018</ArticleId><ArticleId IdType="pubmed">21714940</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkmann A, Koopman G, Mooij P, Verschoor EJ, Verstrepen BE, Bogers W, Idorn M, Paludan SR, Vang S, Nielsen MA, Sander AF, Schmittwolf C, Hochrein H, Chaplin P (2022) A capsid virus-like particle-based SARS-CoV-2 vaccine induces high levels of antibodies and protects rhesus macaques. Front Immunol 13:857440</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9037084</ArticleId><ArticleId IdType="pubmed">35479095</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohana Subramanian B, Madhanmohan M, Sriraman R, Chandrasekhar Reddy RV, Yuvaraj S, Manikumar K, Rajalakshmi S, Nagendrakumar SB, Rana SK, Srinivasan VA (2012) Development of foot-and-mouth disease virus (FMDV) serotype o virus-like-particles (VLPS) vaccine and evaluation of its potency. Antiviral Res 96:288–295</Citation><ArticleIdList><ArticleId IdType="pubmed">23043941</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26:1855–1862</Citation><ArticleIdList><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeoung HY, Lee WH, Jeong W, Shin BH, Choi HW, Lee HS, An DJ (2011) Immunogenicity and safety of virus-like particle of the porcine encephalomyocarditis virus in pig. Virol J 8:170</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3119933</ArticleId><ArticleId IdType="pubmed">21492483</ArticleId></ArticleIdList></Reference><Reference><Citation>Kui X, Sun M, Xie T, Wang W, Jiang L, Yan M, Ma K, Li H (2009) The expression, purification, and immunogenicity of a new chimeric virus-like particle. Viral Immunol 22:49–56</Citation><ArticleIdList><ArticleId IdType="pubmed">19210228</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansardi DC, Porter DC, Morrow CD (1991) Coinfection with recombinant vaccinia viruses expressing poliovirus P1 and P3 proteins results in polyprotein processing and formation of empty capsid structures. J Virol 65:2088–2092</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240068</ArticleId><ArticleId IdType="pubmed">1848318</ArticleId></ArticleIdList></Reference><Reference><Citation>Urakawa T, Ferguson M, Minor PD, Cooper J, Sullivan M, Almond JW, Bishop DH (1989) Synthesis of immunogenic, but non-infectious, poliovirus particles in insect cells by a baculovirus expression vector. J Gen Virol 70:1453–1463</Citation><ArticleIdList><ArticleId IdType="pubmed">2543785</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombaut B, Jore JP (1997) Immunogenic, non-infectious polio subviral particles synthesized in Saccharomyces cerevisiae. J Gen Virol 78:1829–1832</Citation><ArticleIdList><ArticleId IdType="pubmed">9266976</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsian J, Fox H, Bahar MW, Kotecha A, Fry EE, Stuart DI, Macadam AJ, Rowlands DJ, Lomonossoff GP (2017) Plant-made polio type 3 stabilized VLPS-a candidate synthetic polio vaccine. Nat Commun 8:245</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5557999</ArticleId><ArticleId IdType="pubmed">28811473</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherry L, Grehan K, Snowden JS, Knight ML, Adeyemi OO, Rowlands DJ, Stonehouse NJ (2020) Comparative molecular biology approaches for the production of poliovirus virus-like particles using Pichia pastoris. mSphere 5:e00838-19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7067596</ArticleId><ArticleId IdType="pubmed">32161150</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox H, Knowlson S, Minor PD, Macadam AJ (2017) Genetically thermo-stabilised, immunogenic poliovirus empty capsids; a strategy for non-replicating vaccines. PLoS Pathog 13:e1006117</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5245777</ArticleId><ArticleId IdType="pubmed">28103317</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahar MW, Porta C, Fox H, Macadam AJ, Fry EE, Stuart DI (2021) Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines. NPJ Vaccines 6:5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7794334</ArticleId><ArticleId IdType="pubmed">33420068</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherry L, Swanson JJ, Grehan K, Xu H, Uchida M, Jones IM, Stonehouse NJ, Rowlands DJ (2023) Protease-independent production of poliovirus virus-like particles in Pichia pastoris: Implications for efficient vaccine development and insights into capsid assembly. Microbiol Spectr 11:e0430022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9927490</ArticleId><ArticleId IdType="pubmed">36507670</ArticleId></ArticleIdList></Reference><Reference><Citation>Roosien J, Belsham GJ, Ryan MD, King AMQ, Vlak JM (1990) Synthesis of foot-and-mouth disease virus capsid proteins in insect cells using baculovirus expression vectors. J Gen Virol 71:1703–1711</Citation><ArticleIdList><ArticleId IdType="pubmed">2167924</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrams CC, King AMQ, Belsham GJ (1995) Assembly of foot-and-mouth disease virus empty capsids synthesized by a vaccinia virus expression system. J Gen Virol 76:3089–3098</Citation><ArticleIdList><ArticleId IdType="pubmed">8847514</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Yi Y, Yin X, Zhang Z, Liu J (2008) Expression of foot-and-mouth disease virus capsid proteins in silkworm-baculovirus expression system and its utilization as a subunit vaccine. PLoS One 3:e2273</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386233</ArticleId><ArticleId IdType="pubmed">18509464</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Lu Z, Sun J, Bai X, Sun P, Bao H, Chen Y, Guo J, Li D, Liu X, Liu Z (2009) Synthesis of empty capsid-like particles of asia I foot-and-mouth disease virus in insect cells and their immunogenicity in guinea pigs. Vet Microbiol 137:10–17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7117335</ArticleId><ArticleId IdType="pubmed">19167843</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta C, Xu X, Loureiro S, Paramasivam S, Ren J, Al-Khalil T, Burman A, Jackson T, Belsham GJ, Curry S, Lomonossoff GP, Parida S, Paton D, Li Y, Wilsden G, Ferris N, Owens R, Kotecha A, Fry E, Stuart DI, Charleston B, Jones IM (2013) Efficient production of foot-and-mouth disease virus empty capsids in insect cells following down regulation of 3C protease activity. J Virol Methods 187:406–412</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558679</ArticleId><ArticleId IdType="pubmed">23174161</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat SA, Saravanan P, Hosamani M, Basagoudanavar SH, Sreenivasa BP, Tamilselvan RP, Venkataramanan R (2013) Novel immunogenic baculovirus expressed virus-like particles of foot-and-mouth disease (FMD) virus protect guinea pigs against challenge. Res Vet Sci 95:1217–1223</Citation><ArticleIdList><ArticleId IdType="pubmed">23969204</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CD, Yan YP, Liang SM, Wang TF (2009) Production of FMDV virus-like particles by a SUMO fusion protein approach in Escherichia coli. J Biomed Sci 16:69</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2736159</ArticleId><ArticleId IdType="pubmed">19671144</ArticleId></ArticleIdList></Reference><Reference><Citation>Basagoudanavar SH, Hosamani M, Tamil RP, Sreenivasa BP, Chandrasekhar BK, Venkataramanan R (2015) Immunoreactivity and trypsin sensitivity of recombinant virus-like particles of foot-and-mouth disease virus. Acta Virol 59:84–91</Citation><ArticleIdList><ArticleId IdType="pubmed">25790055</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar M, Saravanan P, Jalali SK (2016) Expression and purification of virus like particles (VLPS) of foot-and-mouth disease virus in Eri silkworm (Samia cynthia ricini) larvae. Virusdisease 27:84–90</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758304</ArticleId><ArticleId IdType="pubmed">26925448</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz V, Baztarrica J, Rybicki EP, Meyers AE, Wigdorovitz A (2018) Minimally processed crude leaf extracts of Nicotiana benthamiana containing recombinant foot and mouth disease virus-like particles are immunogenic in mice. Biotechnol Rep 20:e00283</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6180338</ArticleId><ArticleId IdType="pubmed">30319941</ArticleId></ArticleIdList></Reference><Reference><Citation>Veerapen VP, van Zyl AR, Rybicki EP, Meyers AE (2018) Transient expression of heat- and acid-resistant foot-and-mouth disease virus P1–2A mutants in Nicotiana benthamiana. Virus Res 256:45–49</Citation><ArticleIdList><ArticleId IdType="pubmed">30086326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziraldo M, Bidart JE, Prato CA, Tribulatti MV, Zamorano P, Mattion N, D’Antuono AL (2020) Optimized adenoviral vector that enhances the assembly of FMDV O1 virus-like particles in situ increases its potential as vaccine for serotype O viruses. Front Microbiol 11:591019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7672010</ArticleId><ArticleId IdType="pubmed">33250878</ArticleId></ArticleIdList></Reference><Reference><Citation>Mignaqui AC, Ferella A, Cass B, Mukankurayija L, L’Abbé D, Bisson L, Sánchez C, Scian R, Cardillo SB, Durocher Y, Wigdorovitz A (2020) Foot-and-mouth disease: Optimization, reproducibility, and scalability of high-yield production of virus-like particles for a next-generation vaccine. Front Vet Sci 7:601</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7538550</ArticleId><ArticleId IdType="pubmed">33173790</ArticleId></ArticleIdList></Reference><Reference><Citation>Puckette M, Primavera V, Martel E, Barrera J, Hurtle W, Clark B, Kamicker B, Zurita M, Brake D, Neilan J (2022) Transiently transfected mammalian cell cultures: an adaptable and effective platform for virus-like particle-based vaccines against foot-and-mouth disease virus. Viruses 14:989</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9147724</ArticleId><ArticleId IdType="pubmed">35632734</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S, Dong H, Sun S, Guo H (2023) Construction of foot-and-mouth disease virus like particles-induced expression vectors and screening of BHK-21 cell pools. Sheng Wu Gong Cheng Xue Bao 39:4849–4860</Citation><ArticleIdList><ArticleId IdType="pubmed">38147986</ArticleId></ArticleIdList></Reference><Reference><Citation>Du P, Liu R, Sun S, Dong H, Zhao R, Tang R, Dai J, Yin H, Luo J, Liu Z, Guo H (2019) Biomineralization improves the thermostability of foot-and-mouth disease virus-like particles and the protective immune response induced. Nanoscale 11:22748–22761</Citation><ArticleIdList><ArticleId IdType="pubmed">31599276</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo M, Li J, Teng Z, Ren M, Dong H, Zhang Y, Ru J, Du P, Sun S, Guo H (2021) Four simple biomimetic mineralization methods to improve the thermostability and immunogenicity of virus-like particles as a vaccine against foot-and-mouth disease. Vaccines 9:891</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8402440</ArticleId><ArticleId IdType="pubmed">34452016</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng Z, Hou F, Bai M, Li J, Wang J, Wu J, Ru J, Ren M, Sun S, Guo H (2022) Bio-mineralization of virus-like particles by metal-organic framework nanoparticles enhances the thermostability and immune responses of the vaccines. J Mater Chem B 10:2853–2864</Citation><ArticleIdList><ArticleId IdType="pubmed">35319039</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, Chen CY, Lin SY, Chung YC, Chiu HY, Chi WK, Lin YL, Chiang BL, Chen WJ, Hu YC (2010) Enterovirus 71 virus-like particle vaccine: Improved production conditions for enhanced yield. Vaccine 28:6951–6957</Citation><ArticleIdList><ArticleId IdType="pubmed">20797455</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Gao F, Wang X, Shi L, Zhou Z, Jiang Y, Ma X, Zhang C, Zhou C, Zeng X, Liu G, Fan J, Mao Q, Shi L (2020) Development and characterization of an enterovirus 71 (EV71) virus-like particles (VLPS) vaccine produced in Pichia pastoris. Hum Vaccin Immunother 16:1602–1610</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7482752</ArticleId><ArticleId IdType="pubmed">31403352</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Zhou C, Gao F, Zhu Q, Jiang Y, Ma X, Hu Y, Shi L, Wang X, Zhang C, Liu B, Shen L, Mao Q, Liu G (2021) Preclinical evaluation of recombinant hfmd vaccine based on enterovirus 71 (EV71) virus-like particles (VLP): Immunogenicity, efficacy and toxicology. Vaccine 39:4296–4305</Citation><ArticleIdList><ArticleId IdType="pubmed">34167837</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HY, Han JF, Qin CF, Chen R (2013) Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 31:3281–3287</Citation><ArticleIdList><ArticleId IdType="pubmed">23726823</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsou YL, Lin YW, Shao HY, Yu SL, Wu SR, Lin HY, Liu CC, Huang C, Chong P, Chow YH (2015) Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth disease. PLoS Negl Trop Dis 9:e0003692</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4391779</ArticleId><ArticleId IdType="pubmed">25855976</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YJ, Liu WT, Stark H, Huang CT (2015) Expression of enterovirus 71 virus-like particles in transgenic enoki (Flammulina velutipes). Appl Microbiol Biotechnol 99:6765–6774</Citation><ArticleIdList><ArticleId IdType="pubmed">25957149</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu S, Sun S, Dong H, Bai M, Zhang Y, Teng Z, Ren M, Yin S, Guo H (2020) Potent protective immune responses to Senecavirus induced by virus-like particle vaccine in pigs. Vaccines 8:532</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7565160</ArticleId><ArticleId IdType="pubmed">32942760</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Ru Y, Tian H, Ma K, Hao R, Li Y, Luo J, Shi Z, Liu H, Zuo Z, Zheng H (2021) Generation and immunogenicity evaluation of senecavirus A virus-like particles. Sheng Wu Gong Cheng Xue Bao 37:3211–3220</Citation><ArticleIdList><ArticleId IdType="pubmed">34622629</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Wang P, Li Z, Xie Y, Jin N, Han J, Zhang H, Lu H (2024) Construction and immunogenicity of senecavirus A virus-like particle vaccine with adjuvant. Vet Microbiol 289:109971</Citation><ArticleIdList><ArticleId IdType="pubmed">38181599</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeoung HY, Lee WH, Jeong W, Ko YJ, Choi CU, An DJ (2010) Immune responses and expression of the virus-like particle antigen of the porcine encephalomyocarditis virus. Res Vet Sci 89:295–300</Citation><ArticleIdList><ArticleId IdType="pubmed">20378136</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A, Gu L, Wu S, Zhu S (2018) Duck hepatitis a virus structural proteins expressed in insect cells self-assemble into virus-like particles with strong immunogenicity in ducklings. Vet Microbiol 215:23–28</Citation><ArticleIdList><ArticleId IdType="pubmed">29426402</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Yan K, Feng Y, Huang X, Ku Z, Cai Y, Liu F, Shi J, Huang Z (2012) A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine 30:6642–6648</Citation><ArticleIdList><ArticleId IdType="pubmed">22959985</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Parham NJ, Zhang F, Aasa-Chapman M, Gould EA, Zhang H (2012) Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis. Vaccine 30:2301–2308</Citation><ArticleIdList><ArticleId IdType="pubmed">22306858</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta C, Kotecha A, Burman A, Jackson T, Ren J, Loureiro S, Jones IM, Fry EE, Stuart DI, Charleston B (2013) Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen. PLoS Pathog 9:e1003255</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3609824</ArticleId><ArticleId IdType="pubmed">23544011</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SY, Chiu HY, Chiang BL, Hu YC (2015) Development of EV71 virus-like particle purification processes. Vaccine 33:5966–5973</Citation><ArticleIdList><ArticleId IdType="pubmed">25939279</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S (2002) Emerging biological materials through molecular self-assembly. Biotechnol Adv 20:321–339</Citation><ArticleIdList><ArticleId IdType="pubmed">14550019</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo D, Yan C, Wang T (2015) Interparticle forces underlying nanoparticle self-assemblies. Small 11:5984–6008</Citation><ArticleIdList><ArticleId IdType="pubmed">26436692</ArticleId></ArticleIdList></Reference><Reference><Citation>Vert M, Doi Y, Hellwich K-H, Hess M, Hodge P, Kubisa P, Rinaudo M, Schué F (2012) Terminology for biorelated polymers and applications (IUPAC recommendations 2012). Pure Appl Chem 84:377–410</Citation></Reference><Reference><Citation>Mamo T, Poland GA (2012) Nanovaccinology: the next generation of vaccines meets 21st century materials science and engineering. Vaccine 30:6609–6611</Citation><ArticleIdList><ArticleId IdType="pubmed">23067445</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Kim JD, Seo SU (2022) Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2. J Microbiol 60:335–346</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8795728</ArticleId><ArticleId IdType="pubmed">35089583</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam JP, Lu YA, Yang JL (2002) Antimicrobial dendrimeric peptides. Eur J Biochem 269:923–932</Citation><ArticleIdList><ArticleId IdType="pubmed">11846794</ArticleId></ArticleIdList></Reference><Reference><Citation>Cubillos C, de la Torre BG, Jakab A, Clementi G, Borrás E, Bárcena J, Andreu D, Sobrino F, Blanco E (2008) Enhanced mucosal immunoglobulin a response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide. J Virol 82:7223–7230</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2446959</ArticleId><ArticleId IdType="pubmed">18448530</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao J, Wu P (2022) A meta-analysis: the efficacy and effectiveness of polypeptide vaccines protect pigs from foot and mouth disease. Sci Rep 12:21868</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9763257</ArticleId><ArticleId IdType="pubmed">36536158</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupriianova MA, Zhmak MN, Koroev DO, Chepurkin AV, Vol’pina OM, Ivanov VT (2000) Synthetic peptide designs based on immunoactive fragments of the VP1 protein of the foot-and-mouth disease virus strain A22. Bioorg Khim 26:926–932</Citation><ArticleIdList><ArticleId IdType="pubmed">11195591</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco E, Guerra B, de la Torre BG, Defaus S, Dekker A, Andreu D, Sobrino F (2016) Full protection of swine against foot-and-mouth disease by a bivalent B-cell epitope dendrimer peptide. Antiviral Res 129:74–80</Citation><ArticleIdList><ArticleId IdType="pubmed">26956030</ArticleId></ArticleIdList></Reference><Reference><Citation>Soria I, Quattrocchi V, Langellotti C, Gammella M, Digiacomo S, Garcia de la Torre B, Andreu D, Montoya M, Sobrino F, Blanco E, Zamorano P (2017) Dendrimeric peptides can confer protection against foot-and-mouth disease virus in cattle. PLoS One 12:e0185184</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5614567</ArticleId><ArticleId IdType="pubmed">28949998</ArticleId></ArticleIdList></Reference><Reference><Citation>Cañas-Arranz R, Forner M, Defaus S, Rodríguez-Pulido M, de León P, Torres E, Bustos MJ, Borrego B, Sáiz M, Blanco E, Andreu D, Sobrino F (2020) A bivalent B-cell epitope dendrimer peptide can confer long-lasting immunity in swine against foot-and-mouth disease. Transbound Emerg Dis 67:1614–1622</Citation><ArticleIdList><ArticleId IdType="pubmed">31994334</ArticleId></ArticleIdList></Reference><Reference><Citation>Pishavar E, Oroojalian F, Salmasi Z, Hashemi E, Hashemi M (2021) Recent advances of dendrimer in targeted delivery of drugs and genes to stem cells as cellular vehicles. Biotechnol Prog 37:e3174</Citation><ArticleIdList><ArticleId IdType="pubmed">33987965</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma AK, Gothwal A, Kesharwani P, Alsaab H, Iyer AK, Gupta U (2017) Dendrimer nanoarchitectures for cancer diagnosis and anticancer drug delivery. Drug Discov Today 22:314–326</Citation><ArticleIdList><ArticleId IdType="pubmed">27671487</ArticleId></ArticleIdList></Reference><Reference><Citation>Truffi M, Fiandra L, Sorrentino L, Monieri M, Corsi F, Mazzucchelli S (2016) Ferritin nanocages: a biological platform for drug delivery, imaging and theranostics in cancer. Pharmacol Res 107:57–65</Citation><ArticleIdList><ArticleId IdType="pubmed">26968122</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborti S, Chakrabarti P (2019) Self-assembly of ferritin: structure, biological function and potential applications in nanotechnology. Adv Exp Med Biol 1174:313–329</Citation><ArticleIdList><ArticleId IdType="pubmed">31713204</ArticleId></ArticleIdList></Reference><Reference><Citation>Proudhon D, Briat JF, Lescure AM (1989) Iron induction of ferritin synthesis in soybean cell suspensions. Plant Physiol 90:586–590</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1061765</ArticleId><ArticleId IdType="pubmed">16666812</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews SC, Harrison PM, Guest JR (1989) Cloning, sequencing, and mapping of the bacterioferritin gene (bfr) of Escherichia coli K-12. J Bacteriol 171:3940–3947</Citation><ArticleIdList><ArticleId IdType="pmc">PMC210146</ArticleId><ArticleId IdType="pubmed">2661540</ArticleId></ArticleIdList></Reference><Reference><Citation>David CN, Easterbrook K (1971) Ferritin in the fungus Phycomyces. J Cell Biol 48:15–28</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2108231</ArticleId><ArticleId IdType="pubmed">5545102</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida M, Kang S, Reichhardt C, Harlen K, Douglas T (2010) The ferritin superfamily: supramolecular templates for materials synthesis. Biochim Biophys Acta 1800:834–845</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3763752</ArticleId><ArticleId IdType="pubmed">20026386</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai W, Chai B, Feng S, Zhuang X, Ma J, Pang M, Pan L, Yang Z, Tian M, Cheng G (2022) Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant. Signal Transduct Target Ther 7:173</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9157036</ArticleId><ArticleId IdType="pubmed">35650183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kar U, Khaleeq S, Garg P, Bhat M, Reddy P, Vignesh VS, Upadhyaya A, Das M, Chakshusmathi G, Pandey S, Dutta S, Varadarajan R (2022) Comparative immunogenicity of bacterially expressed soluble trimers and nanoparticle displayed influenza hemagglutinin stem immunogens. Front Immunol 13:890622</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9204493</ArticleId><ArticleId IdType="pubmed">35720346</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu Z, Wiehe K, Saunders KO, Henderson R, Cain DW, Parks R, Martik D, Mansouri K, Edwards RJ, Newman A, Lu X, Xia SM, Eaton A, Bonsignori M, Montefiori D, Han Q, Venkatayogi S, Evangelous T, Wang Y, Rountree W, Korber B, Wagh K, Tam Y, Barbosa C, Alam SM, Williams WB, Tian M, Alt FW, Pardi N, Weissman D, Haynes BF (2022) mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Cell Rep 38:110514</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8922439</ArticleId><ArticleId IdType="pubmed">35294883</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Mariz FC, Zhao X, Spagnoli G, Ottonello S, Müller M (2020) Broad neutralization responses against oncogenic human papillomaviruses induced by a minor capsid l2 polytope genetically incorporated into bacterial ferritin nanoparticles. Front Immunol 11:606569</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7746619</ArticleId><ArticleId IdType="pubmed">33343580</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu Y, Zhang B, Wang Y, Yin S, Sun Y, Middelberg A, Bi J (2021) Immunogenicity and vaccine efficacy boosted by engineering human heavy chain ferritin and chimeric hepatitis B virus core nanoparticles. ACS Appl Bio Mater 4:7147–7156</Citation><ArticleIdList><ArticleId IdType="pubmed">35006946</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong H, Qi M, Pan J, Sun Y, Gao J, Zhang X, Li W, Zhang B, Zhang XE, Cui Z (2022) Self-assembling nanovaccine confers complete protection against Zika virus without causing antibody-dependent enhancement. Front Immunol 13:905431</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9124840</ArticleId><ArticleId IdType="pubmed">35615356</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Xu L, Yu H, Lv P, Lei Z, Zeng Y, Liu G, Cheng T (2019) Ferritin nanocage-based antigen delivery nanoplatforms: epitope engineering for peptide vaccine design. Biomater Sci 7:1794–1800</Citation><ArticleIdList><ArticleId IdType="pubmed">30888360</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315–1317</Citation><ArticleIdList><ArticleId IdType="pubmed">4001944</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonas G, Hoffmann S, Willbold D (2001) Binding of phage-displayed HIV-1 Tat to TAR RNA in the presence of cyclin T1. J Biomed Sci 8:430–436</Citation><ArticleIdList><ArticleId IdType="pubmed">11549886</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Guo P, Chen C, Feng H, Zhang W, Gu C, Wen G, Rao VB, Tao P (2021) Bacteriophage T4 vaccine platform for next-generation influenza vaccine development. Front Immunol 12:745625</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8546227</ArticleId><ArticleId IdType="pubmed">34712234</ArticleId></ArticleIdList></Reference><Reference><Citation>Davenport BJ, Catala A, Weston SM, Johnson RM, Ardanuy J, Hammond HL, Dillen C, Frieman MB, Catalano CE, Morrison TE (2022) Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease. NPJ Vaccines 7:57</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9135756</ArticleId><ArticleId IdType="pubmed">35618725</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren ZJ, Tian CJ, Zhu QS, Zhao MY, Xin AG, Nie WX, Ling SR, Zhu MW, Wu JY, Lan HY, Cao YC, Bi YZ (2008) Orally delivered foot-and-mouth disease virus capsid protomer vaccine displayed on T4 bacteriophage surface: 100% protection from potency challenge in mice. Vaccine 26:1471–1481</Citation><ArticleIdList><ArticleId IdType="pubmed">18289743</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemi H, Pouyanfard S, Bandehpour M, Noroozbabaei Z, Kazemi B, Saelens X, Mokhtari-Azad T (2012) Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza a virus challenge. PLoS One 7:e45765</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3454340</ArticleId><ArticleId IdType="pubmed">23029232</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CL, Yong CY, Lee KW (2022) Phage T7 as a potential platform for vaccine development. Methods Mol Biol 2412:75–93</Citation><ArticleIdList><ArticleId IdType="pubmed">34918242</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CL, Yong CY, Muhamad A, Syahir A, Omar AR, Sieo CC, Tan WS (2018) A 12-residue epitope displayed on phage T7 reacts strongly with antibodies against foot-and-mouth disease virus. Appl Microbiol Biotechnol 102:4131–4142</Citation><ArticleIdList><ArticleId IdType="pubmed">29564523</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P, Yin X, Liu Q, Wu W, Chen C (2021) Recombinant T7 phage with FMDV AKT-III strain VP1 protein is a potential FMDV vaccine. Biotechnol Lett 43:35–41</Citation><ArticleIdList><ArticleId IdType="pubmed">32989662</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Bao X, Lu Y, Liu Y, Deng B, Wang Y, Xu Y, Hou J (2017) Immunogenicity of T7 bacteriophage nanoparticles displaying G-H loop of foot-and-mouth disease virus (FMDV). Vet Microbiol 205:46–52</Citation><ArticleIdList><ArticleId IdType="pubmed">28622860</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao P, Mahalingam M, Kirtley ML, van Lier CJ, Sha J, Yeager LA, Chopra AK, Rao VB (2013) Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines. PLoS Pathog 9:e1003495</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3708895</ArticleId><ArticleId IdType="pubmed">23853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao J, Wu P (2024) A meta-analysis on the potency of foot-and-mouth disease vaccines in different animal models. Sci Rep 14:8931</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11026367</ArticleId><ArticleId IdType="pubmed">38637656</ArticleId></ArticleIdList></Reference><Reference><Citation>Vragniau C, Bufton JC, Garzoni F, Stermann E, Rabi F, Terrat C, Guidetti M, Josserand V, Williams M, Woods CJ, Viedma G, Bates P, Verrier B, Chaperot L, Schaffitzel C, Berger I, Fender P (2019) Synthetic self-assembling addomer platform for highly efficient vaccination by genetically encoded multiepitope display. Sci Adv 5:2853</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763337</ArticleId><ArticleId IdType="pubmed">31620562</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevillard C, Amen A, Besson S, Hannani D, Bally I, Dettling V, Gout E, Moreau CJ, Buisson M, Gallet S, Fenel D, Vassal-Stermann E, Schoehn G, Poignard P, Dagher MC, Fender P (2022) Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform. Mol Ther 30:1913–1925</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8828441</ArticleId><ArticleId IdType="pubmed">35151843</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo C, Yan Q, Huang J, Liu J, Li Y, Wu K, Li B, Zhao M, Fan S, Ding H, Chen J (2022) Using self-assembling ADDomer platform to display B and T epitopes of type o foot-and-mouth disease virus. Viruses 14:1810</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9416097</ArticleId><ArticleId IdType="pubmed">36016432</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao-Milán R, Liz-Marzán LM (2014) Gold nanoparticle conjugates: Recent advances toward clinical applications. Expert Opin Drug Deliv 11:741–752</Citation><ArticleIdList><ArticleId IdType="pubmed">24559075</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateu Ferrando R, Lay L, Polito L (2020) Gold nanoparticle-based platforms for vaccine development. Drug Discov Today Technol 38:57–67</Citation><ArticleIdList><ArticleId IdType="pubmed">34895641</ArticleId></ArticleIdList></Reference><Reference><Citation>Pramanik A, Gao Y, Patibandla S, Mitra D, McCandless MG, Fassero LA, Gates K, Tandon R, Chandra Ray P (2021) The rapid diagnosis and effective inhibition of coronavirus using spike antibody attached gold nanoparticles. Nanoscale Adv 3:1588–1596</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8323809</ArticleId><ArticleId IdType="pubmed">34381960</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Liu Y, Chen Z, Li W, Liu Y, Wang L, Liu Y, Wu X, Ji Y, Zhao Y, Ma L, Shao Y, Chen C (2012) Surface-engineered gold nanorods: promising DNA vaccine adjuvant for HIV-1 treatment. Nano Lett 12:2003–2012</Citation><ArticleIdList><ArticleId IdType="pubmed">22372996</ArticleId></ArticleIdList></Reference><Reference><Citation>Quach QH, Ang SK, Chu JJ, Kah JCY (2018) Size-dependent neutralizing activity of gold nanoparticle-based subunit vaccine against dengue virus. Acta Biomater 78:224–235</Citation><ArticleIdList><ArticleId IdType="pubmed">30099200</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng Z, Sun S, Luo X, Zhang Z, Seo H, Xu X, Huang J, Dong H, Mu S, Du P, Zhang Z, Guo H (2021) Bi-functional gold nanocages enhance specific immunological responses of foot-and-mouth disease virus-like particles vaccine as a carrier and adjuvant. Nanomedicine 33:102358</Citation><ArticleIdList><ArticleId IdType="pubmed">33484882</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Xie H, Zhang Z, Wen B, Cao H, Bai Y, Che Q, Guo J, Su Z (2022) Applications and biocompatibility of mesoporous silica nanocarriers in the field of medicine. Front Pharmacol 13:829796</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8832880</ArticleId><ArticleId IdType="pubmed">35153797</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo RR, Lozano D, González B, Manzano M, Izquierdo-Barba I, Vallet-Regí M (2019) Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update. Expert Opin Drug Deliv 16:415–439</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6667337</ArticleId><ArticleId IdType="pubmed">30897978</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo HC, Feng XM, Sun SQ, Wei YQ, Sun DH, Liu XT, Liu ZX, Luo JX, Yin H (2012) Immunization of mice by hollow mesoporous silica nanoparticles as carriers of porcine circovirus type 2 ORF2 protein. Virol J 9:108</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3443011</ArticleId><ArticleId IdType="pubmed">22691538</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahony D, Cavallaro AS, Mody KT, Xiong L, Mahony TJ, Qiao SZ, Mitter N (2014) In vivo delivery of bovine viral diahorrea virus, E2 protein using hollow mesoporous silica nanoparticles. Nanoscale 6:6617–6626</Citation><ArticleIdList><ArticleId IdType="pubmed">24811899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai M, Dong H, Su X, Jin Y, Sun S, Zhang Y, Yang Y, Guo H (2019) Hollow mesoporous silica nanoparticles as delivery vehicle of foot-and-mouth disease virus-like particles induce persistent immune responses in guinea pigs. J Med Virol 91:941–948</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6594029</ArticleId><ArticleId IdType="pubmed">30701562</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Z, Zamanian-Daryoush M, Nie H, Silva AM, Williams BR, Li X (2003) Poly(I-C)-induced toll-like receptor 3 (TLR3)-mediated activation of NFkappa B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR. J Biol Chem 278:16713–16719</Citation><ArticleIdList><ArticleId IdType="pubmed">12609980</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546–549</Citation><ArticleIdList><ArticleId IdType="pubmed">7700380</ArticleId></ArticleIdList></Reference><Reference><Citation>Terhuja M, Saravanan P, Tamilselvan RP (2015) Comparative efficacy of virus like particle (VLP) vaccine of foot-and-mouth-disease virus (FMDV) type O adjuvanted with poly I: C or CpG in guinea pigs. Biologicals 43:437–443</Citation><ArticleIdList><ArticleId IdType="pubmed">26493006</ArticleId></ArticleIdList></Reference><Reference><Citation>Moradi Vahdat M, Hemmati F, Ghorbani A, Rutkowska D, Afsharifar A, Eskandari MH, Rezaei N, Niazi A (2021) Hepatitis B core-based virus-like particles: a platform for vaccine development in plants. Biotechnol Rep 29:e00605</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7937989</ArticleId><ArticleId IdType="pubmed">33732633</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng L, Wang Y, Du J (2020) Human papillomavirus vaccines: an updated review. Vaccines 8:391</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7565290</ArticleId><ArticleId IdType="pubmed">32708759</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Bing Z, Guan S, Zhang Z, Wang X (2018) Development of new hepatitis E vaccines. Hum Vaccin Immunother 14:2254–2262</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6183316</ArticleId><ArticleId IdType="pubmed">29708836</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang YF, Sun C, Zhuang Z, Yuan RY, Zheng Q, Li JP, Zhou PP, Chen XC, Liu Z, Zhang X, Yu XH, Kong XW, Zhu QY, Zhong Q, Xu M, Zhong NS, Zeng YX, Feng GK, Ke C, Zhao JC, Zeng MS (2021) Rapid development of SARS-CoV-2 spike protein receptor-binding domain self-assembled nanoparticle vaccine candidates. ACS Nano 15:2738–2752</Citation><ArticleIdList><ArticleId IdType="pubmed">33464829</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer PJM, Antanasijevic A, Berndsen Z, Yasmeen A, Fiala B, Bijl TPL, Bontjer I, Bale JB, Sheffler W, Allen JD, Schorcht A, Burger JA, Camacho M, Ellis D, Cottrell CA, Behrens AJ, Catalano M, Del Moral-Sanchez I, Ketas TJ, LaBranche C, van Gils MJ, Sliepen K, Stewart LJ, Crispin M, Montefiori DC, Baker D, Moore JP, Klasse PJ, Ward AB, King NP, Sanders RW (2019) Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. Nat Commun 10:4272</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6753213</ArticleId><ArticleId IdType="pubmed">31537780</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyoglu-Barnum S, Ellis D, Gillespie RA, Hutchinson GB, Park YJ, Moin SM, Acton OJ, Ravichandran R, Murphy M, Pettie D, Matheson N, Carter L, Creanga A, Watson MJ, Kephart S, Ataca S, Vaile JR, Ueda G, Crank MC, Stewart L, Lee KK, Guttman M, Baker D, Mascola JR, Veesler D, Graham BS, King NP, Kanekiyo M (2021) Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature 592:623–628</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8269962</ArticleId><ArticleId IdType="pubmed">33762730</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinicaltrials.Gov. https://clinicaltrials.gov/.</Citation></Reference><Reference><Citation>Cansino biologics inc. https://www.Cansinotech.Com.Cn/html/1///179/180/2330.Html.</Citation></Reference><Reference><Citation>Zhang YN, Poon W, Tavares AJ, McGilvray ID, Chan WCW (2016) Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination. J Control Release 240:332–348</Citation><ArticleIdList><ArticleId IdType="pubmed">26774224</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar M, Kulkarni P, Liu S, Chemuturi N, Shah DK (2023) Nanoparticle biodistribution coefficients: a quantitative approach for understanding the tissue distribution of nanoparticles. Adv Drug Deliv Rev 194:114708</Citation><ArticleIdList><ArticleId IdType="pubmed">36682420</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques Neto LM, Kipnis A, Junqueira-Kipnis AP (2017) Role of metallic nanoparticles in vaccinology: implications for infectious disease vaccine development. Front Immunol 8:239</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5340775</ArticleId><ArticleId IdType="pubmed">28337198</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YN, Lazarovits J, Poon W, Ouyang B, Nguyen LNM, Kingston BR, Chan WCW (2019) Nanoparticle size influences antigen retention and presentation in lymph node follicles for humoral immunity. Nano Lett 19:7226–7235</Citation><ArticleIdList><ArticleId IdType="pubmed">31508968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingston NJ, Snowden JS, Martyna A, Shegdar M, Grehan K, Tedcastle A, Pegg E, Fox H, Macadam AJ, Martin J, Hogle JM, Rowlands DJ, Stonehouse NJ (2023) Production of antigenically stable enterovirus A71 virus-like particles in Pichia pastoris as a vaccine candidate. J Gen Virol 104:001867</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10773253</ArticleId><ArticleId IdType="pubmed">37390009</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Li S, Su J, Ma X, Ali A, Xie J, Ma Z, Feng R (2023) Construction, expression and assemble of EMCV VLPs and their potency evaluation. Virology 584:1–8</Citation><ArticleIdList><ArticleId IdType="pubmed">37167793</ArticleId></ArticleIdList></Reference><Reference><Citation>Soria I, Quattrocchi V, Langellotti C, Pérez-Filgueira M, Pega J, Gnazzo V, Romera S, Schammas J, Bucafusco D, Di Giacomo S, de la Torre BG, Andreu D, Sobrino F, Blanco E, Zamorano P (2018) Immune response and partial protection against heterologous foot-and-mouth disease virus induced by dendrimer peptides in cattle. J Immunol Res 2018:3497401</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5960557</ArticleId><ArticleId IdType="pubmed">29854834</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>